Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XVR 011

Next Previous
X
Search
Drug Profile

XVR 011

Alternative Names: VHH SARS-COV-2 THERAPY - ExeVir Bio; VHH72-Fc; XVR-011

Latest Information Update: 28 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ExeVir Bio; Ghent University
  • Developer ExeVir Bio
  • Class Antivirals; Immunoglobulin Fc fragments; Monoclonal antibodies; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II COVID 2019 infections

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In volunteers) in Belgium (IV)
  • 22 Mar 2022 ExeVir Bio terminates phase I/II trial in COVID-2019 infections (Adjunctive treatment) in Belgium, Italy, Moldova (IV) (EudraCT2020-005299-36) (NCT04884295)
  • 18 Aug 2021 Phase-I clinical trials in COVID-2019 infections (In volunteers) in Belgium (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top